Learn how AMCP is helping professionals and stakeholders navigate the application of precision medicine in managed care pharmacy to improve patient outcomes, lower drug costs, end ensure better medication management.
Explore the poster abstract on precision oncology in the 2024 JMCP supplement.
Lung cancer is the most common cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. The National Institutes of Health estimated that cancer care cost the US $208.9 billion in 2020, $23.8 billion of which was due to lung cancer.
To understand the appropriate and cost-effective use of biomarker-driven treatment selection in NSCLC, AMCP convened an expert panel of managed care stakeholders.
This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer.
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
